Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cat-PAD in Cat Allergic Subjects
NCT00685711Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Jan 2008
- Primary completion
- Jul 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Cat-PAD in cat allergy (4 arms), sponsored by NIOX Group. Primary endpoint: Safety and tolerability of Cat-PAD at 21 days. Started Jan 2008; status: completed.
02
Drugs
Cat-PAD
03
Conditions
cat allergy
Beyond the preview
Go deeper on NCT00685711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685711.